Oncology & Hematology Coding Alert

News You Can Use:

Don't Miss Your Chance for Eloxitan Coverage

Plus: The NPI revolution forces a CMS-1500 update

CMS has a duo of announcements that may change the way you operate every day: 1. Count on CMS to Cover These Off-Label Trial Drugs Good news if you participate in colorectal cancer trials. CMS announced it will cover the use of oxaliplatin (Eloxatin), irinotecan (Camptosar), cetuximab (Erbitux), or bevacizumab (Avastin) in clinical trials identified by CMS and sponsored by the National Cancer Institute (NCI).

You can find the list of identified trials on the CMS Web site www.cms.hhs.gov/coverage/download/id90b.pdf or on the Web site publishing the decision (www.cms.hhs.gov/mcd/viewdecisionmemo.asp?id=90) under Appendix A. 2. Prepare for New CMS-1500 If you still submit Medicare claims on paper, start using up that stack of forms. To accommodate the switch to the National Provider Identifier (NPI), Medicare is replacing CMS-1500 (12/90) with CMS-1500 (08/05). You can start using the new form as early as Oct. 1, 2006, but you won't be required to use it until Feb. 1, 2007.

Find out more at www.cms.hhs.gov/MLNMattersArticles/downloads/MM4293.pdf.
You’ve reached your limit of free articles. Already a subscriber? Log in.
Not a subscriber? Subscribe today to continue reading this article. Plus, you’ll get:
  • Simple explanations of current healthcare regulations and payer programs
  • Real-world reporting scenarios solved by our expert coders
  • Industry news, such as MAC and RAC activities, the OIG Work Plan, and CERT reports
  • Instant access to every article ever published in Revenue Cycle Insider
  • 6 annual AAPC-approved CEUs
  • The latest updates for CPT®, ICD-10-CM, HCPCS Level II, NCCI edits, modifiers, compliance, technology, practice management, and more

Other Articles in this issue of

Oncology & Hematology Coding Alert

View All